Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer

Annals of Oncology

Volumn 13, Issue 4, 2002, Pages 582-588

  Amado, R G ^a   Rosen, L S ^a   Hecht, L S ^a   Rosen, P J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 fluorouracil; 5 FU modulation; Antifolates; Infusional 5 FU; Pancreatic cancer; Trimetrexate

Indexed keywords

ANTIBIOTIC AGENT; DIHYDROFOLATE REDUCTASE; FLUOROURACIL; FOLINIC ACID; TRIMETREXATE GLUCURONATE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; SEPSIS; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; GLUCURONATES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PALLIATIVE CARE; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TRIMETREXATE;

EID: 0036242148     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf090     Document Type: Article

References (37)

1. Pancreatic carcinoma
2. Cancer statistics, 1999
3. Chemotherapy for pancreatic carcinoma
4. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
5. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma
6. A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas
7. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial
8. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma
9. 5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: A pilot study
10. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
11. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer
12. A randomized trial of protracted venous infusion 5-fluorouracil with or without mitomycin-C in advanced pancreatic cancer
13. Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: A Mid-Atlantic Oncology Program Study
14. Cisplatin and protracted venous infusion 5-fluorouracil (CF)-good symptom relief with low toxicity in advanced pancreatic carcinoma
15. Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: A phase II study
16. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer
17. Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties
18. Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia
19. Folate and antifolate pharmacology
20. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice
21. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma
22. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells
23. Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vincristine, cytoxan, 6-thioguanine, cisplatin, or 5-fluorouracil against intraperitoneally implanted P388 leukemia
24. Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: Implications for the mechanism of this interaction
25. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer
26. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules
27. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells
28. Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation
29. Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: Evidence for an ordered mechanism
30. Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin
31. 5-Fluorouracil-methotrexate synergy: Enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates
32. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks
33. Phase I studies with trimetrexate: Clinical pharmacology, analytical methodology, and pharmacokinetics
34. Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group
35. Phase II study of trimetrexate glucuronate in the treatment of advanced carcinoma of the pancreas
36. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
37. Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study